Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasuhiro Endo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Junko Arakawa

    Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan (Drs Endo, Teramoto, Arakawa, Suenaga, Sasaki, and Ikewaki)

    2 shared publications
  • Makoto Ayaori

    Tokorozawa Heart Center, Saitama, Japan (Dr Ayaori)

    2 shared publications
  • Yumiko Suenaga

    Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan (Drs Endo, Teramoto, Arakawa, Suenaga, Sasaki, and Ikewaki)

    2 shared publications
  • Genta Toshima

    Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan

    1 shared publication
  • Harumi Uto-Kondo

    Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College

    1 shared publication
  • Hideaki Nakayama

    Department of Somnology, Tokyo Medical University, Tokyo, Japan

    1 shared publication

Latest Publications

  • Open Access

    High-density lipoprotein (HDL) dysfunctionality in autoimmune connective tissue diseases: protocol for a systematic review

    by Yasuhiro Endo, Kei Sasaki, Masatsune Ogura

    Introduction Autoimmune connective tissue diseases (AICTDs) are associated with both chronic inflammation and an increased risk of atherosclerotic cardiovascular disease beyond that conferred by traditional risk factors. High-density lipoprotein (HDL) exerts anti-atherogenic effects through its cholesterol efflux capacity (CEC), which inflammation may impair. Although HDL dysfunction has been reported in AICTDs, the role of this dysfunction in connective tissue diseases has not yet been systematically evaluated. Methods and analysis The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251183500). From inception, the Medical Literature Analysis and Retrieval System Online, Excerpta Medica database and the Cochrane Central Register of Controlled Trials will be searched. The review is scheduled to run from October 2026 to August 2027. Observational and interventional studies in adults with AICTDs reporting quantitative measures of HDL functionality, including CEC, antioxidant capacity, anti-inflammatory function and endothelial protective function, will be included. The study will be independently conducted by two reviewers. Ethics and dissemination Because this study will be a systematic review based on previously published data and will not involve individual patient data, ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and will be presented at a conference. PROSPERO registration number CRD420251183500.

  • Obstructive sleep apnea syndrome attenuated high-density lipoprotein function

    by Yasuhiro Endo, Manami Teramoto, Junko Arakawa, Shoko Ukita, Genta Toshima, Yumiko Suenaga, Kei Sasaki, Makoto Ayaori, Hideaki Nakayama, Yuichi Inoue, et al.


  • Open Access

    Liver-specific LXR inhibition represses reverse cholesterol transport in cholesterol-fed mice

    by Takafumi Nishida, Makoto Ayaori, Junko Arakawa, Yumiko Suenaga, Kazusa Shiotani, Harumi Uto-Kondo, Tomohiro Komatsu, Kazuhiro Nakaya, Yasuhiro Endo, Makoto Sasaki, et al.

    Objective: High density lipoprotein (HDL) exerts an anti-atherosclerotic effect via reverse cholesterol transport (RCT). Several phases of RCT are transcriptionally controlled by Liver X receptors (LXRs). Although macrophage LXRs reportedly promote RCT, it is still uncertain whether hepatic LXRs affect RCT in vivo . Approach and Results: To address this question, we induced hepatic overexpression of sulfotransferase family cytosolic 2B member 1 (Sult2b1) in mice. Sult2b1 facilitates generation of sulfated cholesterol, resulting in reduced production of LXR ligands (oxysterols), which impairs LXR signaling. Adenoviral vectors expressing Sult2b1 (Ad-Sult2b1) or luciferase were intravenously injected into mice under a normal or high-cholesterol diet. Hepatic Sult2b1 overexpression resulted in reduced expression of LXR-target genes - ATP-binding cassette transporter G5/G8, cholesterol 7α hydroxylase and LXRα itself - respectively reducing or increasing cholesterol levels in HDL and apolipoprotein B–containing lipoproteins (apoB-L). A macrophage RCT assay revealed that Sult2b1 overexpression inhibited fecal excretion of macrophage-derived 3 H-cholesterol only under a high-cholesterol diet. In a HDL kinetic study, Ad-Sult2b1 promoted catabolism/hepatic uptake of HDL-derived cholesterol, thereby reducing fecal excretion. We next performed an in vitro lipoprotein production assay which revealed a Sult2b1-mediated reduction/increase in HDL or apoB-L secretion from hepatocytes, respectively. Finally, in LXRα/β double knockout mice, hepatic Sult2b1 overexpression increased apoB-L levels, but there were no differences in HDL levels or RCT compared to the control, indicating that Sult2b1-mediated effects on HDL/RCT and apoB-L were distinct: the former was LXR-dependent, but not the latter. Conclusions: Hepatic LXR inhibition negatively regulates circulating HDL levels and RCT by reducing LXR-target gene expression. Graphic

  • Open Access

    HDL Functions—Current Status and Future Perspectives

    by Yasuhiro Endo, Masanori Fujita, Katsunori Ikewaki

    Cardiovascular disease (CVD) is the leading cause of death in Western countries. A low HDL-C is associated with the development of CVD. However, recent epidemiology studies have shown U-shaped curves between HDL-C and CVD mortality, with paradoxically increased CVD mortality in patients with extremely high HDL-C levels. Furthermore, HDL-C raising therapy using nicotinic acids or CETP inhibitors mostly failed to reduce CVD events. Based on this background, HDL functions rather than HDL-C could be a novel biomarker; research on the clinical utility of HDL functionality is ongoing. In this review, we summarize the current status of HDL functions and their future perspectives from the findings of basic research and clinical trials.